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other four symptoms in the 24-26% range. Multivariate
logistic regression was used to analyze predictors with
a cutoff of >3 symptoms. Participants currently on medica-
tion for cGVHD (OR¼2.32, P ¼ .003) and females (OR¼1.72,
P ¼ .04) were more likely to report 3 or more symptoms.
There was a reduced likelihood of reporting 3 or more
symptoms for every 5 years post-treatment (OR¼.72, P ¼
.008) and for participants with incomes more than $60,000
per year (OR¼.59, P ¼ .04).
Discussion: Risk for long-term symptoms after HCT was
associated with ongoing cGVHD treatment, being female, as
well as shorter time since transplant and lower income. Future
research needs to examine how treatment and demographic
factors interact as either risk or protective factors for symptom
burden and identify strategies to reduce symptoms.220
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Design: Case control analytic study
Objectives: To investigate risk factors for developing dry eye
in adult patients after hematopoietic stem cell trans-
plantation (HSCT). Secondarily, to assess severity of dry eye
and tear proﬁles in these patients.
Methods: This study was conducted from May 2011-June
2012. Seventy-eight adult patients who underwent HSCT for
various hematologic disorders at King Chulalongkorn
Memorial Hospital were enrolled in this study. Two patients
were excluded due to underlying lid abnormalities that
might cause dry eye. Dry eye was diagnosed using stan-
dardized questionnaire, tear break-up time, Schirmer test
and ﬂuorescein and rose bengal staining. Of 76 patients, 40
patients (52.6%) had dry eye and they served as the case
group. Thirty-six patients who did not meet the criteria
served as the control group. Patient's charts were reviewed
for clinical data, HSCT details and complications. The main
outcome measures were dry eye occurrence, severity and
tear proﬁles.
Results: 24 of 48 patients (50%) who received allografts and
16 of 28 patients (57.1%) who received autografts had dry eye
after HSCT. Peripheral blood was used as stem cell source in
96% of the patients. Dry eye manifestation was found to be
positively correlated with age over 35 years, duration of
systemic cyclosporine use and chronic graft-versus-host
disease (GVHD) of the oral cavity (P ¼ .049, P ¼ .010 and .002
respectively, by univariate analysis). Using binary logistic
regression, we found only chronic oral GVHD to be strongly
associated with dry eye occurrence (P ¼ .006, odds ratio¼
9.15, 95% CI 1.91-43.87). Fluorescein and rose bengal staining
were classiﬁed in signiﬁcantly higher grading in allogeneic
than the autologous group (P < .001 and P ¼ .007 respec-
tively, Mann-Whitney Test). Of 18 patients who had severe
dry eye, 13 (72.2%) were in allogeneic and 5 (27.8%) were in
autologous group.
Conclusion: Dry eye is a very common ocular manifestation
after autologous and allogeneic HSCT, albeit more severe in
allogeneic HSCT. In allogeneic transplant patients, closeattention to the development of chronic oral GVHD may lead
to early diagnosis of dry eye in these patients.POSTER SESSION 1: LEUKEMIA
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Between 1994 and 2011 343 adult patients with acute
myeloid leukemia (AML) underwent allogeneic stem cell
transplantation (SCT). 244 pts were transplanted in CR 1, CR 2
or CR 3 and 99 pts were transplanted with active disease. 56/
99 pts were male, 43/99 pts were female. Median age was 50
years (17 e 70). 65 pts had primary AML, 22 pts secondary
AML afterMDS and 12 pts had therapy related (t-AML). 45/99
pts had induction failure (primary refractory), in 3/99 pts
AML was untreated (Fanconi, SCID, active NHL), 39/99 pts
were transplanted for AML in ﬁrst relapse and 12/99 pts were
transplanted for AML in second relapse. Median blast count
in the bonemarrow before conditioningwas 20 % (5e 90). 21
pts had extramedullary leukemia, mainly meningeosis and
skin involvement. Karyotype was intermediate in 60 pts and
high risk in 33 pts. In 5 pts karyotype analysis was not done,
in 1 patient favourable. Induction failure was deﬁned as blast
persistence after two cycles of chemotherapy including high
dose ARAC. Pts transplanted in ﬁrst relapse had an untreated
relapse (n ¼ 15) or had received another chemotherapy. Pts
with meningeosis had received intrathecal therapy. Donors
for SCT were HLA identical siblings in 35/99 pts or unrelated
donors in 64/99 pts. Conditioning regimen was myeloa-
blative (MAC) (12 Gy TBI + CY) in 42 pts (since 1995), reduced
intensity conditioning (RIC) (FLU/ BU/ATG) in 42 pts (since
1998) and FLAMSA-RIC in 15 pts (since 2007).
Results: After allogeneic SCT 4/99 pts had progression of
leukemia, 95/99 went in remission. 24/99 pts are alive, 4
with AML and 20 pts in CCR. Median remission duration of
the 20 pts in CCR is 47 months (0.5 - 130). 75/99 pts are dead.
Causes of death are leukemia in 48/75 and TRM in 27/75 pts,
mainly gvhd and infection. Probability of survival at 60
months, 90 months and 120 months for the whole group is
0.26, 0.19 and 0.08, respectively. The stage of disease at
conditioning had no signiﬁcant inﬂuence. Probability of
survival at 60 months and 90 months for primary refractory
pts was 0.3 and 0.22, in ﬁrst relapse 0.26 und 0.13 and in
second relapse 0.19 and 0.19. The conditioning regimen was
not randomized and showed a trend for better survival in RIC
vs. MAC vs. FLAMSA RIC, at 60 months 0.42 vs. 0.17 vs. 0.1 (at
30 months), at 90 months 0.25 vs. 0.14.
Conclusion: After induction failure or after ﬁrst relapse SCT
is the only curative therapy. About 25% of the pts can enjoy
